Articles Published in 2013

Boston Scientific opens China Innovation Center

Wednesday, September 18, 2013 11:25 AM

Boston Scientific, a global medical technology company, has opened the China branch of the Boston Scientific Institute for Advancing Science (IAS) as well as its new Innovation Center. Boston Scientific expects to foster local talent while sustainably developing innovative technologies uniquely suited to the China market.

More... »

Texas Heart Institute, TAMU receive $3m for biotechnology center

Wednesday, September 18, 2013 11:04 AM

The Texas Heart Institute (THI) and Texas A&M University (TAMU) College of Veterinary Medicine and Biomedical Sciences have received a $3 million grant through the Texas Emerging Technology Fund (TETF) to create the Center for Cell and Organ Biotechnology

More... »

Report: More than 270 vaccines in biopharmaceutical pipelines

Wednesday, September 18, 2013 11:01 AM

America’s biopharmaceutical companies are currently developing 271 vaccines to prevent and treat conditions including infectious diseases, cancer and neurological disorders, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

More... »

Cardiome, Tzamal Medical form commercialization agreement

Wednesday, September 18, 2013 10:57 AM

Cardiome Development, a subsidiary of Cardiome Pharma, and Tzamal Medical Group are collaborating to sell and distribute Brinavess (vernakalant intravenous) exclusively in Israel. Tzamal Medical, a private group of companies providing medical devices and equipment for the healthcare industry, has agreed to specific annual commercial goals for Brinavess, which was approved in Europe for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. Financial details of the agreement have not been disclosed.

More... »

IRB Services selects Intralinks VIA

Wednesday, September 18, 2013 10:47 AM

IRB Services (Institutional Review Board Services), a global provider of research ethics review and related services for the clinical research and behavioral science industries, has selected Intralinks VIA to support all of its secure beyond the firewall collaboration needs. Intralinks is a global SaaS provider of inter-enterprise content management and collaboration solutions.

More... »

MIT awarded $25m for human computer development

Wednesday, September 18, 2013 10:42 AM

The National Science Foundation (NSF) has awarded $25 million to establish a Center for Brains, Minds and Machines at the Massachusetts Institute of Technology (MIT). The center is one of three new research centers funded this year through NSF's Science and Technology Centers: Integrative Partnerships program.

More... »

Treato Pharma launches new version of "patient voice" intelligence

Wednesday, September 18, 2013 10:40 AM

Treato, the source of "patient voice" intelligence, has announced the new version of its Treato Pharma platform for pharmaceutical companies and agencies.

More... »

Chiesi to acquire 100% of Cornerstone Therapeutics

Wednesday, September 18, 2013 09:04 AM

European pharma company Chiesi Farmaceutici will acquire 100% of Cornerstone Therapeutics, a North Carolina-based specialty pharmaceutical company commercializing products for the U.S. hospital and adjacent specialty markets.

More... »

Boehringer Ingelheim collaborates with Presidio Pharmaceuticals

Monday, September 16, 2013 03:12 PM

Boehringer Ingelheim has completed patient enrollment for a phase IIa clinical trial (NCT01859962) investigating a new interferon-free, all-oral, direct-acting antiviral (DAA) combination treatment for patients with genotype-1a chronic hepatitis C virus (HCV) infection. This trial is conducted in collaboration with Presidio Pharmaceuticals and evaluates Boehringer Ingelheim’s investigational compounds, the protease inhibitor faldaprevir (BI 201335) and non-nucleoside NS5B polymerase inhibitor, deleobuvir (BI 207127), in combination with Presidio’s investigational pan-genotypic NS5A inhibitor, PPI-668, with and without ribavirin.

More... »

Analysis highlights predictive biomarkers discovery for Vectibix

Monday, September 16, 2013 03:11 PM

Amgen has published a biomarker analysis of Vectibix (panitumumab) in combination with FOLFOX, a type of oxaliplatin-based chemotherapy, for the first-line treatment of patients with metastatic colorectal cancer (mCRC). Published in the New England Journal of Medicine, the analysis found that RAS mutations, beyond the known KRAS exon 2 mutations, predict lack of response to Vectibix in combination with FOLFOX. RAS mutations are mutations occurring in exons 2, 3 and 4 of KRAS and NRAS.

More... »